Renal transplantationComplicationNew Onset Dyslipidemia After Renal Transplantation: Is There a Difference Between Tacrolimus and Cyclosporine?
Section snippets
Patients and methods
Two hundred ninety-five patients were transplanted between January 1995 and October 2000 in our center. After exclusion of patients with diabetes mellitus, retransplants, those treated with rapamycin, and those who died or lost their graft within the first year, 202 patients were included in this retrospective study.
The patients were treated with thymoglobuline, steroids, azathioprine, or mycophenolate mofetil (MMF) and Tac (76 patients) or CsA (126 patients). Tac and CsA doses were adapted
Demographic Characteristics
The day of transplantation, the groups were similar concerning mean age (43.4 vs 45 years), body mass index (22.4 vs 23.5), haemoglobin (11.2 vs 10.9 g/dL), prevalence of arterial hypertension (24% vs 28%), and the use of hypolipemic agents (5.4% vs 8.4%) in Tac vs CsA groups, respectively. No difference was observed at 12 months concerning graft function: creatinine clearance (47.4 vs 49.6 mL/minute and proteinuria 0.47 vs 0.64 g/24 hour) or the mean doses of steroids (18 vs 19 at 1 month and
Discussion
Although the study was retrospective, our results show that lipid abnormalities are frequently observed in our recipients the day of transplant and that the CsA, but not Tac, increases these abnormalities after transplantation. In fact, as already reported by others, we observed an increase in the prevalence of hyperTC from 29% to 57% in the CsA group and only from 26 to 29% in the Tac group. More interstingly, incidence of de novo hyperTC, which more precisely defines the role of the
References (9)
- et al.
Small dense low-density lipoprotein in renal transplant recipients: A potential target for prevention of cardiovascular complications?
Transplant Proc
(2006) - et al.
Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients
Transplant Proc
(2000) - et al.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Lancet
(2003) - et al.
Hyperlipidemia after renal transplantation: natural history and pathophysiology
Ann Intern Med
(1979)
Cited by (29)
Managing dyslipidemia in solid organ transplant patients
2024, Indian Heart JournalCardiovascular and metabolic disease in the liver transplant recipient
2020, Best Practice and Research: Clinical GastroenterologyCitation Excerpt :CNIs affect multiple aspects of lipid metabolism, of which the most commonly cited mechanism is inhibition of LDL receptor-mediated lipoprotein clearance, although pathways not involving LDL receptors are suspected as well [31]. Cyclosporine has been consistently shown to cause more dyslipidemia in post-solid organ transplant patients compared to tacrolimus [32,33]; switching from cyclosporine to tacrolimus has been shown to decrease LDL and triglyceride levels [34,35]. The mTOR inhibitors tend to increase triglycerides and LDL.
Correlation between CD14+CD16++ monocytes in peripheral blood and hypertriglyceridemia after allograft renal transplantation
2013, Transplantation ProceedingsCitation Excerpt :The incidence of the newly-onset hypercholesterolemia and hyperlow-density lipoprotein-cholesterolemias were both significantly lower in the tacrolimus than the CsA group: 8% vs 28% and 31% vs 65% (P < .001), respectively. However, neither the differences in TG and HDL-C between groups nor the rates of HTG were significantly different.6 Monocyte infiltration is a characteristic of the damage caused by HTG.
Drugs that act on the immune system: Immunosuppressive and immunostimulatory drugs
2009, Side Effects of Drugs AnnualCitation Excerpt :By multivariate Cox regression analysis, age over 60 years, a BMI over 30 kg/m2, and immunosuppression with tacrolimus were associated with diabetes mellitus after transplantation. Of 295 patients after renal transplantation, 76 were given tacrolimus and 126 ciclosporin (10c). Lipid concentrations were similar in the two groups at day 0.
Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents
2023, Journal of the American Society of Nephrology